Harmony Biosciences Holdings, Inc. $HRMY Stock Holdings Cut by Bridge City Capital LLC

Bridge City Capital LLC reduced its stake in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) by 8.8% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 237,103 shares of the company’s stock after selling 22,840 shares during the period. Harmony Biosciences makes up approximately 2.6% of Bridge City Capital LLC’s portfolio, making the stock its 2nd biggest position. Bridge City Capital LLC’s holdings in Harmony Biosciences were worth $8,872,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Public Sector Pension Investment Board raised its holdings in Harmony Biosciences by 41.6% in the 3rd quarter. Public Sector Pension Investment Board now owns 185,803 shares of the company’s stock valued at $5,121,000 after buying an additional 54,605 shares during the period. Ruffer LLP purchased a new stake in Harmony Biosciences in the 4th quarter valued at about $1,536,000. American Century Companies Inc. raised its holdings in Harmony Biosciences by 11.2% in the 3rd quarter. American Century Companies Inc. now owns 1,669,565 shares of the company’s stock valued at $46,013,000 after buying an additional 168,145 shares during the period. LSV Asset Management raised its holdings in Harmony Biosciences by 7.1% in the 3rd quarter. LSV Asset Management now owns 1,594,893 shares of the company’s stock valued at $43,955,000 after buying an additional 106,391 shares during the period. Finally, State of New Jersey Common Pension Fund D purchased a new stake in Harmony Biosciences in the 3rd quarter valued at about $1,572,000. 86.23% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several analysts recently issued reports on the stock. UBS Group reduced their price objective on shares of Harmony Biosciences from $46.00 to $36.00 and set a “neutral” rating on the stock in a report on Wednesday, February 25th. Zacks Research upgraded shares of Harmony Biosciences from a “strong sell” rating to a “hold” rating in a report on Friday, May 1st. Needham & Company LLC reduced their price objective on shares of Harmony Biosciences from $46.00 to $44.00 and set a “buy” rating on the stock in a report on Wednesday, February 25th. Wall Street Zen lowered shares of Harmony Biosciences from a “buy” rating to a “hold” rating in a research note on Saturday, February 28th. Finally, Deutsche Bank Aktiengesellschaft lowered shares of Harmony Biosciences from a “buy” rating to a “hold” rating and set a $31.00 price target on the stock. in a research note on Monday, February 23rd. Four equities research analysts have rated the stock with a Buy rating, six have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $40.89.

Harmony Biosciences Stock Down 2.1%

Shares of NASDAQ:HRMY opened at $34.46 on Friday. The company has a debt-to-equity ratio of 0.15, a current ratio of 3.58 and a quick ratio of 3.56. The firm has a market capitalization of $1.99 billion, a PE ratio of 13.90, a price-to-earnings-growth ratio of 0.24 and a beta of 0.96. The firm’s 50-day moving average is $30.86 and its two-hundred day moving average is $33.14. Harmony Biosciences Holdings, Inc. has a 1 year low of $25.52 and a 1 year high of $40.87.

Harmony Biosciences (NASDAQ:HRMY) last issued its quarterly earnings results on Thursday, May 7th. The company reported $0.55 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.76 by ($0.21). The business had revenue of $215.39 million for the quarter, compared to analysts’ expectations of $220.84 million. Harmony Biosciences had a return on equity of 17.19% and a net margin of 16.20%.The firm’s revenue for the quarter was up 16.6% on a year-over-year basis. During the same quarter last year, the company earned $0.78 earnings per share. Analysts predict that Harmony Biosciences Holdings, Inc. will post 3.2 EPS for the current year.

About Harmony Biosciences

Harmony Biosciences Holdings, Inc is a commercial?stage biopharmaceutical company focused on developing and delivering therapies for people with rare neurological and endocrine diseases. Founded in 2017 and headquartered in Plymouth Meeting, Pennsylvania, Harmony Biosciences went public in 2020 and trades on the Nasdaq under the ticker HRMY. The company’s mission centers on identifying and advancing medicines that address critical unmet needs in patient populations underserved by existing treatments.

The company’s flagship product is WAKIX (pitolisant), the first and only histamine H3 receptor antagonist/inverse agonist approved by the U.S.